Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Protein or biologic · Fusion protein
Detailed molecular class: Protein/biologic; confirm exact product
Supplied sequence or chemical reference
Mechanism
GLP-1 receptor agonist fused to an Fc component; biologic distinct from semaglutide.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Cardiovascular and vascular function
Authorized type 2 diabetes treatment and reduction of certain cardiovascular events per Trulicity labeling; do not substitute other agonists’ obesity research.
Human evidence
REWIND studied cardiovascular outcomes in type 2 diabetes. An authorized product’s indications do not authenticate catalog dulaglutide.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
REWIND studied cardiovascular outcomes in type 2 diabetes. An authorized product’s indications do not authenticate catalog dulaglutide.
REWIND studied cardiovascular outcomes in type 2 diabetes. An authorized product’s indications do not authenticate catalog dulaglutide.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
EU: Trulicity is authorized for insufficiently controlled type 2 diabetes in patients ≥10 years with diet/exercise and label conditions. Commercial material does not inherit authorization.
Adverse effects and unknowns
Gastrointestinal, pancreatic/biliary risks and hypoglycemia with insulin/secretagogues. US MTC/MEN2 contraindication; verify jurisdictional labeling.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Dulaglutide · 142 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT05478707 · Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesRegistry status: RecruitingLast update posted: October 15, 2026Query verification: October 16, 2026
NCT07668336 · A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRegistry status: Not yet recruitingLast update posted: September 25, 2026Query verification: October 16, 2026
NCT07834398 · Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesRegistry status: CompletedLast update posted: September 22, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-TRU
October 16, 2026
- PMID31189511
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators.
October 16, 2026
- SEARCH-PUBMED-dulaglutide
PubMed/MED targeted search: TITLE:dulaglutide AND TITLE:REWIND
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026